Andreas G. Weichert founded Dr. WEICHERT - LIFE SCIENCES CONSULTING in 2007, recognizing the increasing demand for flexible external resources to deliver R&D project data in a complex and changing environment. While predominantly been involved in industrial drug discovery and development, he more recently has also provided support in sustained delivery issues researching biomaterial and nanotech approaches for combination products in the medical device field.
Before, Dr. Weichert held international positions with increasing responsibility for more than 18 years. His experience covers the entire spectrum of early and preclinical drug discovery & development - from academic research on anti-tumor antibiotics at Stanford University, CA, USA, to managing a discovery chemistry department in Big Pharma.
In his scientific and managerial assignments at AVENTIS PHARMA and ELI LILLY & Co. he gained a broad understanding about all aspects of the pharmaceutical R&D value chain, contributing to and directing projects in all major therapeutic areas, with a focus on diabetes and cardiovascular indications. Under his leadership, several research compounds were successfully advanced into the clinic. As a member of the global discovery management team at ELI LILLY & Co. he was involved in diabetes project portfolio management and led the implementation of process innovations as well as outsourcing efforts.
Since 2011 Dr. Weichert has also served as independent expert for evaluations in FP7 and Horizon 2020 health programmes of the EUROPEAN COMMISION. He is a member of the editorial advisory board of Pharmaceutical Patent Analyst, Future Science Ltd, London, UK. For more details see